Audiomedica.com
Pembrolizumab: No Survival Gains Second Line In Gastric Cancer
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:00:07
- Mas informaciones
Informações:
Sinopsis
Reporter: Sarah Maxwell BARCELONA—Pembrolizumab did not significantly improve overall survival (OS) or progression free survival (PFS) compared with paclitaxel as second-line therapy in patients with advanced gastric or gastro-esophageal junction cancer that had progressed after one line of chemotherapy (containing …Kohei Shitara Audio Journal of Oncology
